The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Open accessAbstract
The use of monoclonal antibodies (mAbs) as therapeutic tools has increased dramatically in the last decade and is now one of the mainstream strategies to treat cancer. Nonetheless, it is still not completely understood how mAbs mediate tumor cell elimination or the effector cells that are involved. Using intravital microscopy, we found that antibody-dependent phagocytosis (ADPh) by macrophages is a prominent mechanism for removal of tumor cells from the circulation in a murine tumor cell opsonization model. Tumor cells were rapidly recognized and arrested by liver macrophages (Kupffer cells). In the absence of mAbs, Kupffer cells sampled tumor cells; however, this sampling was not sufficient for elimination. By contrast, antitumor mAb treatment resulted in rapid phagocytosis of tumor cells by Kupffer cells that was dependent on the high-affinity IgG-binding Fc receptor (FcγRI) and the low-affinity IgG-binding Fc receptor (FcγRIV). Uptake and intracellular degradation were independent of reactive oxygen or nitrogen species production. Importantly, ADPh prevented the development of liver metastases. Tumor cell capture and therapeutic efficacy were lost after Kupffer cell depletion. Our data indicate that macrophages play a prominent role in mAb-mediated eradication of tumor cells. These findings may help to optimize mAb therapeutic strategies for patients with cancer by helping us to aim to enhance macrophage recruitment and activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“When mice were deficient for the inhibitory receptor FcγRII, antitumor mAb therapy was, by contrast, more effective in preventing tumor development (9).”
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Davies, L. C., Jenkins, S. J., Allen, J. E., & Taylor, P. R. (2013) · Nature Immunology · doi:10.1038/ni.2705 · Cited by 2,096
Rooijen, N. V., & Sanders, A. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90012-4 · Cited by 1,779
Macrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830 · cited 4×
“For instance, mutations in EGFR signaling pathways in colorectal cancer seriously interfere with therapeutic success of anti-EGFR mAbs (6).”
InfluentialB7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748 · cited 1×
“For instance, Kupffer cells in hepatocellular carcinoma had higher expression of the B7-H1 molecule, which suppressed CD8 + T cell function through interaction with programmed death-1 on CD8 + T cells (36, 37).”
FcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Redox signaling in macrophages
Jay Forman, H. (2001) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(01)00010-3 · Cited by 510
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
Functional Innervation of Hepatic iNKT Cells Is Immunosuppressive Following Stroke
Wong, C. H. Y., Jenne, C. N., Lee, W.-Y., Léger, C., & Kubes, P. (2011) · Science · doi:10.1126/science.1210301 · Cited by 396
Self-citationWu, K., Kryczek, I., Chen, L., Zou, W., & Welling, T. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0901 · Cited by 380
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 348
Rahbari, N. N., Aigner, M., Thorlund, K., Mollberg, N., Motschall, E., Jensen, K., Diener, M. K., Büchler, M. W., Koch, M., & Weitz, J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.008 · Cited by 308
Ioan-Facsinay, A., de Kimpe, S. J., Hellwig, S. M. M., van Lent, P. L., Hofhuis, F. M. A., van Ojik, H. H., Sedlik, C., da Silveira, S. A., Gerber, J., de Jong, Y. F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00294-7 · Cited by 304
Antibody-Based Immunotherapy of Cancer
Weiner, L. M., Murray, J. C., & Shuptrine, C. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.034 · Cited by 284
Hatjiharissi, E., Xu, L., Santos, D. D., Hunter, Z. R., Ciccarelli, B. T., Verselis, S., Modica, M., Cao, Y., Manning, R. J., Leleu, X., et al. (2007) · Blood · doi:10.1182/blood-2007-01-070656 · Cited by 282
Antibodies, Fc receptors and cancer
Nimmerjahn, F., & Ravetch, J. V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.005 · Cited by 234
Minard-Colin, V., Xiu, Y., Poe, J. C., Horikawa, M., Magro, C. M., Hamaguchi, Y., Haas, K. M., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-01-135160 · Cited by 218
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice
Horikawa, M., Minard-Colin, V., Matsushita, T., & Tedder, T. F. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59266 · Cited by 191
Neutrophils mediate antibody-induced antitumor effects in mice
Albanesi, M., Mancardi, D. A., Jönsson, F., Iannascoli, B., Fiette, L., Santo, J. P. D., Lowell, C. A., & Bruhns, P. (2013) · Blood · doi:10.1182/blood-2013-04-497446 · Cited by 166
Racila, E. V., Link, B. K., Weng, W., Witzig, T. E., Ansell, S. M., Maurer, M. J., Huang, J., Dahle, C. E., Halwani, A. S., Levy, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0745 · Cited by 159
Vijayasaradhi, S., Xu, Y., Bouchard, B., & Houghton, A. N. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.130.4.807 · Cited by 153
Hubert, P., Heitzmann, A., Viel, S., Nicolas, A., Sastre‐Garau, X., Oppezzo, P., Pritsch, O., Osinaga, E., & Amigorena, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4222 · Cited by 132
Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function
Grugan, K. D., McCabe, F. L., Kinder, M., Greenplate, A. R., Harman, B. C., Ekert, J. E., van Rooijen, N., Anderson, G. M., Nemeth, J. A., Strohl, W. R., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201889 · Cited by 126
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Oflazoglu, E., Stone, I. J., Gordon, K. A., Grewal, I. S., van Rooijen, N., Law, C., & Gerber, H. (2007) · Blood · doi:10.1182/blood-2007-06-097014 · Cited by 117
Wind, J., Tuynman, J. B., Tibbe, A. G. J., Swennenhuis, J. F., Richel, D. J., Henegouwen, M. I. V. B., & Bemelman, W. A. (2009) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2008.12.003 · Cited by 100
Bevaart, L., Jansen, M., van Vugt, M. J., Verbeek, J. S., van de Winkel, J. G. J., & Leusen, J. H. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2856 · Cited by 97
Otten, M. A., van der Bij, G. J., Verbeek, S. J., Nimmerjahn, F., Ravetch, J. V., Beelen, R. H. J., van de Winkel, J. G. J., & van Egmond, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6829 · Cited by 89
Myeloid cells as effector cells for monoclonal antibody therapy of cancer
Braster, R., O’Toole, T. G., & van Egmond, M. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.020 · Cited by 82
Self-citationOflazoglu, E., Stone, I. J., Brown, L. L., Gordon, K. A., van Rooijen, N., Jonas, M., Law, C.-L., Grewal, I. S., & Gerber, H.-P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604812 · Cited by 81
Persky, D. O., Dornan, D., Goldman, B. H., Braziel, R. M., Fisher, R. I., LeBlanc, M. L., Maloney, D. G., Press, O. W., Miller, T., & Rimsza, L. M. (2012) · Haematologica · doi:10.3324/haematol.2011.050419 · Cited by 70
van der Bij, G. J., Bögels, M., Otten, M. A., Oosterling, S. J., Kuppen, P. J. K., Meijer, S., Beelen, R. H. J., & van Egmond, M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.023 · Cited by 59
Self-citationA view on EGFR-targeted therapies from the oncogene-addiction perspective
Pérez, R., Crombet, T., de León, J., & Moreno, E. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00053 · Cited by 50
Role of Kupffer cells in the outgrowth of colorectal cancer liver metastases
Paschos, K. A., Majeed, A. W., & Bird, N. C. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00578.x · Cited by 46
Understanding rituximab function and resistance: implications for tailored therapy
Amoroso, A. (2010) · Frontiers in bioscience · doi:10.2741/3719 · Cited by 42
Gül, N., Bögels, M., Grewal, S., van der Meer, A. J., Rojas, L. B., Fluitsma, D. M., van den Tol, M. P., Hoeben, K. A., van Marle, J., de Vries, H. E., et al. (2011) · Gut · doi:10.1136/gut.2010.224717 · Cited by 33
Self-citationTajima, S., Soda, M., Bando, M., Enomoto, M., Yamasawa, H., Ohno, S., Takada, T., SUZUKI, E., Gejyo, F., & Sugiyama, Y. (2008) · Respirology · doi:10.1111/j.1440-1843.2008.01322.x · Cited by 30
Bilitewski, U. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2089-6 · Cited by 20
Cited by
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
Metadata
- Authors
- Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L. M., Kubes, P., & van Egmond, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-16
- Volume
- 124
- Issue
- 2
- Pages
- 812-823
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2117281169
- Cited by
- 275
- References
- 46
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.